Edition:
United States

Profile: Medigen Biotechnology Corp (3176.TWO)

3176.TWO on Gre Tai Securities Market of Chinese Taipei

82.70TWD
5 Dec 2016
Change (% chg)

NT$-0.30 (-0.36%)
Prev Close
NT$83.00
Open
NT$83.00
Day's High
NT$83.00
Day's Low
NT$80.80
Volume
2,161
Avg. Vol
423,128
52-wk High
NT$102.00
52-wk Low
NT$50.60

MEDIGEN BIOTECHNOLOGY CORP. is engaged in the research and development of new drugs and the testing of nucleic acids. It involves in the licensing of technologies, the provision of technical services and the testing of nucleic acids. The Company's products and services include human leukocyte antigen (HLA) ABDR typing reagents, HLA typing and testing services, HLA SBT high-resolution typing reagents, HLA ABCDRDQ typing kits, nucleic acid testing reagents for the genotyping of human platelet, nucleic acid extraction instruments and reagents, and blood screening specialized automated nucleic acid detection platforms. It also involves in the human clinical trials of anti-liver cancer drugs. The Company distributes its products in domestic market and to overseas markets.

Company Address

Medigen Biotechnology Corp

14F, Bldg F, No. 3
Yuancyu St.
Nangang District
TAIPEI     115
P: +8862.26535200
F: +8862.27856120

Company Web Links